The potential for liquid chromatography-high resolution accurate mass (LC-HRAM) spectrometry to identify 'unknown' compounds using non-targeted screening methods provides a potential advantage in the fight against doping in sport. This innovation comes with the requirement for assessment to support its use in the medico-legal context. A method for the LC-HRAM detection of 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) compounds in equine urine was validated in order to assess the capabilities of a workflow developed for non-targeted analysis using the SIEVE® differential analysis software platform. Six NBOMe compounds (25B, 25C, 25D, 25E, 25H and 25I) were studied to develop and optimize the proposed non-targeted screening workflow before two additional candidates (25N and 25T2) were used as blind controls for verification. Chromatographic alignment and the integration threshold were found to be the most critical parameters for successful identification of 'unknown' responses. The proposed workflow serves as an example for anti-doping laboratories to implement fitfor-purpose non-targeted screening methods.
Introduction
Novel psychoactive substances (NPS) are chemical modica-tions of currently controlled substances that have similar pharmacological effects and chemically designed to circumvent legislation. 1 In 2012, Casale and Hays 2 reported the characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) compounds considered to be more potent serotonin 5-HT 2A receptor agonists than their 2,5-dimethoxyphenethylamine ("2C") precursors. [3] [4] [5] Since this time there have been multiple reports concerning adverse health effects. [6] [7] [8] [9] [10] [11] [12] [13] Misuse of this drug class generally occurs with a single administration of approximately 0.1 g to achieve hallucinations and a varying degree of stimulation. 13 In response to a medico-legal requirement the validation of analytical methods used to detect NBOMe compounds in biological matrices has been reported by forensic toxicology laboratories. [8] [9] [10] Furthermore, metabolism studies in human and rat urine have been recently performed.
14 While there are no reports describing the effect of these compounds in horses, there is concern about the potential for misuse of NPS such as NBOMe compounds in equine athletes where handlers may have made the assumption that these compounds are undetectable by horseracing laboratories. The availability of these compounds presents a serious threat to the integrity of equine sports and to the welfare of the horse. NBOMe compounds are therefore prohibited for use by the International Federation of Horseracing Authorities.
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Analytical methods utilizing the sensitivity and specicity of liquid chromatography-high resolution accurate mass (LC-HRAM) spectrometry applied to forensic toxicology, [16] [17] [18] and more specically to horseracing laboratories, 19 have been reported in recent years. The potential for LC-HRAM technology to detect 'unknown' compounds using non-targeted screening methods provides a potential advantage in the ght against doping in sport.
Differential analysis is a tool used in studies with large data sets that require the comparison of pre-treatment control samples of biological origin with samples collected following a treatment (such as exposure to particular stimuli) in order to detect and elucidate biomarkers correlating to the treatment response. The control and treatment samples are compared by statistical means resulting in the generation of a list of targets that are independent of the control sample. For the past 10 to 15 years, differential analysis techniques have been widely used for the assessment of microarray data. 20, 21 More recently following the development of soware for MS-based applications, there is considerable potential for differential analysis in analytical chemistry. 22 Depending on the soware used standard outputs may include retention time, mass-to-charge (m/z) ratio and the statistical probability (p-value) of the two samples being statistically different. From this information, a targeted approach can be applied such as tandem mass spectrometry (MS 2 ) to identify unknown compounds. This strategy is preferred over conventional visual assessment of chromatographic data since it can detect compounds that coelute or have low abundances obscured by background noise. In addition, differential analysis applied to full-scan MS provides an advantage over other chemometric approaches for biomarker detection by not excluding raw data. With the rapid proliferation of NPS such strategies have the potential to detect new compounds that have not been previously dened in published targeted methods or databases. The aim of the study described herein was to develop and validate a method for the detection of six NBOMe compounds ( Fig. 1 ) in equine urine using LC-HRAM spectrometry to support integrity in horseracing. Furthermore, the applicability of using a differential analysis soware package such as SIEVE® (Statistical Iterative Exploratory Visualization Environment, Thermo Fisher Scientic) 23 was evaluated for the non-targeted screening and putative identication of two additional NBOMe compounds that were unknown to the analyst under 'blind' testing conditions.
Materials and methods

Reference materials, chemicals and reagents
Hydrochloride salts of the NBOMe compounds [2-(4- 
Preparation of blank equine urine
Authentic blank urine samples were collected from three thoroughbred gelding horses by spontaneous voiding with carrot reward following approval from the Racing NSW Animal Care and Ethics Committee (RP72). These horses were known to have not been administered any pharmaceutical agent for at least two weeks prior to sample collection. Urine samples from the three horses were pooled to provide a prole considered to be representative of the racehorse population for proof-of-concept concerning differential analysis.
Sample preparation
Equine urine samples (3 mL) were fortied with desipramine-d 3 (2 mg mL
À1
, 50 mL) internal standard before addition of pH 5.0 acetate buffer (0.2 M, 4 mL) followed by enzyme hydrolysis with b-glucuronidase K12 from E. coli (20 mL) and trypsin solution (625 mg per sample) overnight at 37 C. The basic organic fraction was isolated by solid phase extraction (SPE) using a mixedmode C8/strong cation exchange XTRACKT® column (200 mg, 3 cc, UCT, Bristol, PA, USA). The cartridge was conditioned with methanol (2 mL) and water (2 mL) before loading the urine sample and washing with acetic acid (0.1 M, 2 mL) followed by methanol (2 mL). The cartridge was dried using N 2 gas under positive pressure before elution with ethyl acetate/ammonia/ methanol (100 : 3 : 0.5, 3 mL). HCl/methanol (0.1 M, 20 mL) was added to extracts before evaporation to dryness under nitrogen at 60 C. Residues were reconstituted in methanol (50 mL) and 
pH 4 ammonium acetate (10 mM, 100 mL) for LC-HRAM analysis.
LC-HRAM analysis
LC-HRAM spectrometry was undertaken using an Ultimate 3000 HPLC coupled to a QExactive benchtop orbitrap mass spectrometer (Thermo Fisher Scientic, Bremen, Germany). LC separation was performed using a Gemini® C18 column (50 Â 2.1 mm, 5 mm; Phenomenex, Torrence, CA, USA) operating at 35 C with a 10 mL injection volume. The mobile phase consisted of A: pH 9 ammonium acetate (10 mM) and B: 0.1% acetic acid/acetonitrile. Gradient elution was performed with a ow rate of 0.5 mL min À1 according to the following program: 1% B for 2 min, increased to 80% B linearly during the period between 2 and 8.5 min, before returning to 1% B at 8.6 min and held until 11.2 min. HRAM detection was performed using positive mode heated electrospray ionization (HESI) in full scan at a resolution of 70 000 (full width at half maximum, FWHM) acquiring a mass range of m/z 50 to 650 at 3 Hz. Mass calibration was performed prior to analysis using Pierce® ESI positive (P/N 88 323) calibration solution (Thermo Fisher Scientic, Bremen, Germany) but no lock mass was used. Source temperature, spray voltage, sheath gas (high purity N 2 ) and auxiliary gas (ultra-high purity N 2 ) were set at 350 C, +4000 V, + for each analyte provided in Table 1 . The limit of detection (LOD) and lower limit of quantication (LLOQ) for the six candidate NBOMe compounds were determined from replicate (n ¼ 7) analyses of spiked equine urine samples achieving a signal-to-noise (S/N) ratio of greater than 3 and 10, respectively. Intra-and inter-assay precision (expressed as percentage relative standard deviation, %RSD), together with accuracy, were determined from the ratio of peak areas for the analyte and desipramine-d 3 for seven replicates of 1 ng mL
À1
and 10 ng mL À1 each analysed seven days over a period of two weeks. The same spiked sample matrix was used to assess recovery with comparison to urine samples fortied at 1 ng mL À1 and 10 ng mL À1 post-extraction. In turn, matrix effect was assessed using this set of post-extraction fortied urine samples compared to neat standards reconstituted in LC mobile phase at 1 ng mL À1 and 10 ng mL À1 . Long-term stability trials were performed on additional replicates (n ¼ 3) of spiked samples stored at 4 C, À20 C and À80 C for one-, two-and threemonth intervals. Short-term stability freeze/thaw trials were conducted on three consecutive days using additional replicates (n ¼ 3) of spiked samples stored at À20 C.
Non-targeted screening. Differential analysis of full scan (MS 1 ) data was performed using SIEVE® version 2.0.180. Data les acquired from duplicate sample injections were processed against duplicate matrix blank injections representing the control, the second of which was assigned as the reference le for chromatographic alignment. Recursive-base-peak-framing was used over the entire chromatographic run time (11.2 min) between m/z 50 and 500 to reect the retention time and mass range of NPS. The default Peak Intensity Threshold of 1.27 Â 10 8 resulted in the generation of 5000 frames while the optimized Peak Intensity Threshold of 1 Â 10 6 resulted in the generation of 2000 frames, each with a chromatographic time range of 2.5 min and m/z width of 10 ppm. Statistical output from SIEVE® provides a Ratio value between sample and control with an associated p-value for each putative substance. Analysis of MS 2 data to investigate dissociation schemes and apply precursor ion ngerprinting was performed using Mass Frontier™ 7.0 SR1. Each of these soware packages were purchased from Thermo Fisher Scientic (San Jose, CA, USA).
Results and discussion
Targeted method validation
The limited LC selectivity displayed by the six candidate NBOMe compounds is shown in Table 1 with retention times within 0.8 min, including coelution of 25C and 25D. Nevertheless, specicity was achieved from differences in mass for this group of . Intra-and inter-assay precision was assessed at a spiking level of 1 ng mL À1 to be within 8.7% (<10%) and 13.2% (<15%), respectively. At 10 ng mL À1 these were within 4.0% (<10%) and 10.9% (<15%), respectively. Suitability of the SPE sample preparation method was demonstrated by excellent recoveries (88-97%) from 10 ng mL À1 spiked equine urine samples, supporting accuracy between 93 AE 4% and 113 AE 6% (between 80% and 120%). Matrix effects were determined to be negligible from the results that were within 20% of the expected value. Samples were stable aer 3 freeze/thaw cycles and stable for up to 3 months at 4 C, À20 C and À80 C.
Non-targeted analysis using differential analysis
Individual components of the SIEVE® soware workow were assessed; chromatographic alignment, peak detection, statistical analysis and identication. Chromatographic alignment. Since SIEVE® can compare between two or more samples simultaneously, it is important that the sample chromatograms are rst aligned for the peak detection process to provide accurate results. The ChromAlign algorithm corrects for inherent chromatographic variability by calculating optimal correlations between full-scan spectra in separate data les. 27 Retention time results for the six candidate
NBOMe
matrix were compared to assess variation that may reduce the robustness of the alignment algorithm used by SIEVE®. The suitability of LC parameters was demonstrated by relative standard deviations of less than 0.1% determined from seven 10 ng mL À1 replicates over seven sets of analyses conducted within two weeks. Using the example of 25B spiked at 100 ng mL À1 , Fig. 2 demonstrates proof-of-concept for SIEVE® to provide visual identication of an abnormal response. Peak detection. Following chromatographic alignment, spectral data is plotted in three-dimensional space with retention time, m/z and relative intensity on the x-, y-and z-axes, respectively. Peaks in the control and treatment sample are detected using an algorithm called recursive-base-peak-framing where spectral data from both samples in the experiment are grouped together by relative intensity. Once the common base peak is known, a frame is established according to user-dened retention time, m/z and intensity tolerances. 28 The Peak Intensity Threshold is the lowest intensity for which a spectral data point will be framed and is recommended to be one that is representative of the LOD for the respective class.
The default Peak Intensity Threshold setting of 1.27 Â 10 8 analyzing 5000 frames provided detection of the six candidate NBOMe compounds at concentrations between 20 and 100 ng mL À1 . While sufficient for proof-of-concept that differential analysis was applicable to the method, these levels were considered too high for routine application. Optimization of the Peak Intensity Threshold to 1 Â 10 6 analyzing 2000 frames resulted in detection levels between 0.5 ng mL À1 and 10 ng mL À1 that are considered t-for-purpose.
Statistical analysis. At the conclusion of the peak detection process, the mean peak intensity values for peaks in each frame from sample and control replicates are compared using paired t-tests for determination of signicant differences. The generated frame report contains the associated p-value for verication by the user. For simplicity, the frame report also contains a Ratio parameter which provides the user with direct comparison of mean peak intensities that can be ltered to identify compounds of interest. By convention, the maximum Ratio and minimum p-value is 99 999.90 and 1.00 Â 10 À5 , which implies the compound in the treatment sample is completely independent to the control sample. In addition to numerical For this study, compounds exhibiting a Ratio > 10 and pvalue < 0.001 were deemed compounds of interest. Fig. 3 shows the frame report for 25B spiked at 5 ng mL À1 with maximum With the molecular weight and chemical formula proposed for an 'unknown' compound using SIEVE® and Xcalibur®, respectively, the identication process can proceed using MS 2 studies. For this purpose Mass Frontier™ spectral interpretation soware was used to interrogate targeted MS 2 data uploaded from Xcalibur®. Mass Frontier™ soware can predict product-ion structures and provide dissociation pathways for user-dened compounds. Precursor ion ngerprinting was investigated as a means for using structurally-related product ions to identify the precursor. 29 MS 2 studies of the six candidate NBOMe compounds revealed a common dissociation pathway resulting in the cleavage of benzyl moiety to produce m/z 121.0651 (AE1.2 ppm) and detection of the tropylium ion (m/z 91.0548 (AE1.8 ppm)). These diagnostic product ions can be used to conrm the NBOMe class of compounds following investigation of screening abnormalities produced from differential analysis. Proposed workow. The results for 25B were used to propose a workow (Fig. 5 ) that could be implemented by forensic laboratories using differential analysis to perform non-targeted screening. This was successfully applied to the detection of 25C (10 ng mL À1 ), 25D (5 ng mL À1 ), 25E (10 ng mL À1 ), 25H (5 ng mL À1 ) and 25I (0.5 ng mL À1 ) in equine urine. The proposed workow is composed of four sections that are separated based on the soware required; SIEVE®, Xcalibur®, Mass Frontier™ and database searching. At the conclusion of differential analysis by SIEVE®, the frame results can be ltered by Ratio (or pvalue) and components that exhibit a Ratio > 10 and p-value < 0.001 can be selected for further interrogation. Those that do not meet these criteria can be considered as matrix contributions. Since the majority of NBOMe compounds have one nitrogen atom (i.e. an odd number) it would result in an even m/ z value for the precursor ion due to the addition of a proton from the electrospray ionization process. Components that have an odd m/z value can also be included for interrogation since analogues containing an even number of nitrogen atoms are possible, however, odd m/z values can imply that the molecule contains no nitrogen atoms and would result in a larger data set for evaluation. Following differential analysis, the molecular formulae for selected components can be generated in Xcalibur® using the elemental composition tool by including C, H, N, O, F, Cl, Br, I, S as elements of interest. If the formula generated for a particular component contains a single nitrogen with three oxygen atoms and a DBE ¼ 8 it can be subjected to MS 2 studies. The mass error difference should be within AE10 ppm, however, this value can be modied as required by the user. The MS 2 data of selected components can be evaluated for the presence of only two major product ions, specically m/z 121.0648 and 91.0542. The added substituent can be determined by comparing the mass difference of the target analyte and the least substituted analogue 25H-NBOMe. Once the structure has been tentatively identied the likelihood can be assessed by using structural correlation soware such as Mass Frontier™ to compare the in silico and experimental fragmentation patterns. If they correlate, the data can then be compared to a database and if the database search yields no result the analyte of interest could be a novel NBOMe compound. It should be considered that while the strategy outlined here is aimed explicitly at users of Thermo Fisher Scientic hardware-soware congurations for screening of NBOMe compounds, the general workow can be adapted by users of Verication. The proposed workow was subsequently veried by two blind control tests, each performed by a separate analyst with the knowledge that a NBOMe compound was spiked into equine urine at 100 ng mL À1 but not which particular compound it was. 
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Illicit administration of NPS such as NBOMe compounds to racehorses is highly possible in response to surveillance of conventional amphetamine-type substances by laboratories. This requires accredited racing laboratories to implement testing methods for substances that become readily available on the black market in order to deter and prosecute licensed persons who are tempted to administer non-approved drugs without knowledge of adverse health effects to an animal. Since 2013, the Australian Racing Forensic Laboratory (ARFL) has no reported ndings for NBOMe compounds in equine urine.
The challenge of screening for an ever-increasing number of target compounds, many of which may be 'unknown' to a laboratory or for which no reference material is available, necessitates the use of hardware-soware technology combinations that can assist in identifying abnormal responses in a biological sample for further investigation. To this end, the advantages of HRAM instrumentation in racing laboratories can be further enhanced by incorporating differential analysis soware such as SIEVE® investigated in this study.
The individual components of the SIEVE® soware workow were assessed to identify critical control points that could be optimized for a proposed non-targeted analysis workow in forensic laboratories. The importance of mass accuracy for condence in determining unknowns should not be understated. Following the assessment of this parameter to document specicity in method validation, successful differential analysis was shown by this study to be dependent on robustness of chromatographic alignment and optimization of the Peak Intensity Threshold to achieve the required sensitivity. Recursivebase-peak-framing provides retention time, m/z, Ratio, p-value and CompMW that can be reviewed to determine an abnormal nding. While the processing time (approximately 1 min) for differential analysis per sample is reasonable, further work is required to enable batch processing of multiple sample les for more efficient translation of this workow to routine testing. Regardless, the proposed workow was used by the ARFL in conjunction with routine targeted analysis of 95 equine urine samples over a three-week period during a major racing carnival. No abnormalities requiring further investigation have yet been reported, however work continues to increase the coverage of samples analyzed by this method.
The CompMW can be used by the instrument operating soware (Xcalibur®) to provide a putative chemical formula within dened parameters for elemental composition, which is critical to ensure sufficient coverage of NPS that may include halogen and sulfur substituents. In addition, DBE was found to be a useful discriminator of NPS classes, with 8 or 9 (in the case of 25N) being characteristic of NBOMe compounds. Subsequent MS 2 data was interrogated using Mass Frontier™ to enable precursor ion ngerprinting where diagnostic product ions could identify the NBOMe present. The major limitation of this study was the reliance on conventional literature sources to facilitate the nal stage of compound identication from MS 2 data. Further work is required to investigate the possibility that pseudo-MS 3 (using in-source collision-induced dissociation, CID) studies of small molecules such as NBOMe compounds could provide the means for in silico structural elucidation. This would allow collaborative approaches such as mzCloud, 32 a MS n spectral database, to be incorporated into the workow. An additional limitation is the focus on parent NBOMe compounds without taking into account the likely presence of metabolites following NBOMe administration as recently reported for 25I by Caspar et al.
14 Metabolism of NBOMe and other NPS compounds will undoubtedly be important to consider as the research into non-targeted screening strategies continues, however the focus of this study was to use parent NBOMe compounds as model analytes for the development of non-targeted screening strategies.
Consideration must also be given to the presence of isobaric compounds such as structural isomers that are not resolved using HRAM technology. Investigation and subsequent conrmation of such compounds will require greater LC selectivity than the generic screen presented here.
Notwithstanding the limitations of the method, putative identication of a NBOMe compound using the presented screening strategy can enable an abnormality to be recorded against a sample in order for further investigation to take place. Subsequent conrmation would require the procurement of an authentic reference material but this should not preclude the method from being useful to circumvent the nexus that antidoping laboratories nd themselves in terms of targeted analysis.
Conclusion
The use of LC-HRAM spectrometry has demonstrated the capability for laboratories to combat the misuse of NPS in horseracing. Specic to this study, the presented method for the detection and quantication of NBOMe compounds in equine urine was validated. In addition, proof-of-concept use of differential analysis with SIEVE® was performed for non-targeted screening to putatively identify two NBOMe compounds, 25N and 25T2 with scope to extend this study to MS n data for in silico elucidation of novel compounds.
